22.09.2023 12:58:05
|
Seagen Up In Pre-Market After Positive Results From EV-302 Trial
(RTTNews) - Shares of Seagen Inc. (SGEN) are trading up over three percent on Friday after the company released positive results from EV-302 trial.
SGEN was trading up by 3.59 percent at $213.80 per share in the pre-market trade on the Nasdaq.
Seagen and Astellas Pharma Inc. reported positive results from the Phase 3 EV-302 trial for PADCEV in combination with KEYTRUDA versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer.
The drug maker noted the EV-302 study met dual primary endpoints of overall survival and progression-free survival, compared to chemotherapy.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Seattle Genetics Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |